Patients with metastatic NSCLC that developed during previous treatment with PD-L1 were randomized (1:1:1) to receive either durvalumab plus tremelimumab alone or with either low-dose or hypo-fractionated radiotherapy. This evidence concerns the gene CD274 and non-small cell lung carcinoma.